1.Breast-conserving therapy for breast cancer and its prognosis
Jianshan HONG ; Jianrong YANG ; Chuangmin ZHANG ; Jianlun LIU ; Nanwu YANG ; Jiansi CHENG ; Huawei YANG
Chinese Journal of General Surgery 2001;0(09):-
Objective To explore the effect of breast-conserving therapy for breast cancer(BCT) and its prognosis. Methods The clinical data of 69 cases of BCT admitted from January 1992 to December 2003 were analyzed retrospectively. The cases included those who had BCT without radiotherapy and those who had BCT with adjuvant radiotherapy, chemotherapy and hormonal therapy. The patients were followed up for 12 to 140 months. Results The 3-year recurrence rate for patients without radiotherapy (11.54%) was higher than that for those with radiotherapy (3.03%) (P
2.Identification of Bulbocodin D and C as novel STAT3 inhibitors and their anticancer activities in lung cancer cells.
Xinyu HE ; Jiarui FU ; Wenyu LYU ; Muyang HUANG ; Jianshan MO ; Yaxin CHENG ; Yulian XU ; Lijun ZHENG ; Xiaolei ZHANG ; Lu QI ; Lele ZHANG ; Ying ZHENG ; Mingqing HUANG ; Lin NI ; Jinjian LU
Chinese Journal of Natural Medicines (English Ed.) 2023;21(11):842-851
Cancer stands as one of the predominant causes of mortality globally, necessitating ongoing efforts to develop innovative therapeutics. Historically, natural products have been foundational in the quest for anticancer agents. Bulbocodin D (BD) and Bulbocodin C (BC), two bibenzyls derived from Pleione bulbocodioides (Franch.) Rolfe, have demonstrated notable in vitro anticancer activity. In human lung cancer A549 cells, the IC50s for BD and BC were 11.63 and 11.71 μmol·L-1, respectively. BD triggered apoptosis, as evidenced by an upsurge in Annexin V-positive cells and elevated protein expression of cleaved-PARP in cancer cells. Furthermore, BD and BC markedly inhibited the migratory and invasive potentials of A549 cells. The altered genes identified through RNA-sequencing analysis were integrated into the CMap dataset, suggesting BD's role as a potential signal transducer and activator of transcription 3 (STAT3) inhibitor. SwissDock and MOE analyses further revealed that both BD and BC exhibited a commendable binding affinity with STAT3. Additionally, a surface plasmon resonance assay confirmed the direct binding affinity between these compounds and STAT3. Notably, treatment with either BD or BC led to a significant reduction in p-STAT3 (Tyr 705) protein levels, regardless of interleukin-6 stimulation in A549 cells. In addition, the extracellular signal-regulated kinase (ERK) was activated after BD or BC treatment. An enhancement in cancer cell mortality was observed upon combined treatment of BD and U0126, the MEK1/2 inhibitor. In conclusion, BD and BC emerge as promising novel STAT3 inhibitors with potential implications in cancer therapy.
Humans
;
Lung Neoplasms/metabolism*
;
STAT3 Transcription Factor/metabolism*
;
Antineoplastic Agents/chemistry*
;
A549 Cells
;
Apoptosis
;
Cell Line, Tumor
;
Cell Proliferation